Physician profile
Brittney White
NPI 1255920203
$2,074.10
in general payments reported to CMS, 2019-2025
22 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.34 · 2022: $659 · 2023: $603 · 2024: $316 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.49 | 2022-2025 | |
| Novo Nordisk INC | $240.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $230.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.51 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $208.59 | 2022-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $166.54 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $164.04 | 2021-2023 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.25 | 2022-2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $58.80 | 2023-2024 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $58.28 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.69 | 2025 | Caplyta |
| Exact Sciences Corporation | $44.96 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $43.59 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $37.97 | 2022 | |
| Merz North America, INC. | $36.90 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $36.54 | 2021-2023 | Yupelri |
| Pfizer INC. | $29.91 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $28.07 | 2023 | Xarelto |
| Antares Pharma, INC. | $27.27 | 2025 | Xyosted |
| Indivior INC. | $24.05 | 2025 | Sublocade |
| Tolmar, INC. | $20.33 | 2024 | |
| Boston Scientific Corporation | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittney White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.